// App-Quantinova.ai

: SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Researchers

Presenter

  • Jose F. Falantes

Principal Investigators

  • Francisco J. Marquez-Malaver

  • Estrella Carrillo-Cruz

  • Rosario M Morales-Camacho

  • Concepcion Prats-Martin

  • Teresa Caballero

  • Eduardo Rodriguez Arboli

  • Ildefonso Espigado

  • Jose A. Perez-Simon

Medical Centers

  • Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain

  • Hematology Department, Hospital Vírgen del Rocío, Instituto de Biomedicina (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Seville, Spain

  • Department of Hematology, Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Seville, Spain

  • Hematology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Myeloid neoplasms

Biomarkers

  • MPL proto-oncogene, thrombopoietin receptor

  • Calreticulin

  • B-Raf proto-oncogene, serine/threonine kinase

  • Abelson murine leukemia viral oncogene homolog

  • Nucleophosmin 1

  • CCAAT enhancer binding protein alpha

  • Colony stimulating factor 3 receptor

  • Protein Tyrosine Phosphatase, Non-Receptor Type 11

  • GATA-binding protein 2

  • E3 ubiquitin-protein ligase CBL

  • Enhancer of zeste homolog 2

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • KRAS proto-oncogene, GTPase

  • Retinoblastoma protein

  • DNA methyltransferase 3 alpha

  • ETV6-RUNX1

  • GTPase Nras

  • HRas Proto-Oncogene, GTPase

  • Fms related tyrosine kinase 3

  • Isocitrate dehydrogenase 1

  • WT1 Transcription Factor

  • Tet methylcytosine dioxygenase 2

  • Isocitrate dehydrogenase 2

  • Tumor protein p53

  • Neurofibromatosis type 1

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • TP53

  • EZH2

Outcome

  • N/A

Study Design

  • KRAS

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved